LEO Pharma is a global leader in research and development (R&D). We are committed to developing new treatments which aim to fulfil unmet needs and improve the quality of life for people living with dermatological (skin) conditions and thromboembolic (blood clotting) disorders.
The LEO R&D function is the cornerstone of our commitment to patient care, and to the continued success and future growth of LEO Pharma. Seventeen per cent of our global annual turnover is allocated to R&D.
Our multidisciplinary global R&D team draws on a rich heritage of drug development and discovery which dates back more than a century. Today, there are more than 500 scientists and specialists working in our global Discovery, Development, Pharmaceutical Formulation departments, supported by LEO Pharma UK/Ireland (UK/IE)’s Regulatory Affairs and Safety teams, to research new chemical entities and develop novel treatments.
Our internal R&D expertise is further strengthened by our collaboration with more than 400 academic and institutional research centres and industry partners worldwide.
Together, our fully integrated team takes new treatments from microscope to market.
For more information about LEO
At a global level, LEO Pharma is dedicated to developing drugs and therapies that deliver value to people and societies around the world. We are striving to become the leading speciality pharmaceutical company worldwide through our ambition to fulfil unmet treatment needs within our focus area of dermatology.
Working in collaboration with our research partners, LEO Pharma is developing a rich pipeline of products within dermatology.
To find out more visit our global website: www.leo-pharma.com.